Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 101

1.

Prostate cancer and metabolic syndrome: is there a link?

McGrowder DA, Jackson LA, Crawford TV.

Asian Pac J Cancer Prev. 2012;13(1):1-13. Review.

2.

The dark side of testosterone deficiency: III. Cardiovascular disease.

Traish AM, Saad F, Feeley RJ, Guay A.

J Androl. 2009 Sep-Oct;30(5):477-94. doi: 10.2164/jandrol.108.007245. Epub 2009 Apr 2. Review.

3.

Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.

Kintzel PE, Chase SL, Schultz LM, O'Rourke TJ.

Pharmacotherapy. 2008 Dec;28(12):1511-22. doi: 10.1592/phco.28.12.1511. Review.

PMID:
19025432
4.

Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.

Braga-Basaria M, Dobs AS, Muller DC, Carducci MA, John M, Egan J, Basaria S.

J Clin Oncol. 2006 Aug 20;24(24):3979-83.

PMID:
16921050
5.

Metabolic effects of androgen deprivation therapy.

Choi SM, Kam SC.

Korean J Urol. 2015 Jan;56(1):12-8. doi: 10.4111/kju.2015.56.1.12. Epub 2015 Jan 6. Review.

6.

Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.

Shahani S, Braga-Basaria M, Basaria S.

J Clin Endocrinol Metab. 2008 Jun;93(6):2042-9. doi: 10.1210/jc.2007-2595. Epub 2008 Mar 18. Review.

PMID:
18349064
7.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2009 May;181(5):1998-2006; discussion 2007-8. doi: 10.1016/j.juro.2009.01.047. Epub 2009 Mar 14. Review.

9.

Quantifying the evidence for the risk of metabolic syndrome and its components following androgen deprivation therapy for prostate cancer: a meta-analysis.

Bosco C, Crawley D, Adolfsson J, Rudman S, Van Hemelrijck M.

PLoS One. 2015 Mar 20;10(3):e0117344. doi: 10.1371/journal.pone.0117344. eCollection 2015.

10.

Components of the metabolic syndrome and risk of prostate cancer: the HUNT 2 cohort, Norway.

Martin RM, Vatten L, Gunnell D, Romundstad P, Nilsen TI.

Cancer Causes Control. 2009 Sep;20(7):1181-92. doi: 10.1007/s10552-009-9319-x. Epub 2009 Mar 11.

PMID:
19277881
11.

Obesity, metabolic syndrome, and prostate cancer.

Hsing AW, Sakoda LC, Chua S Jr.

Am J Clin Nutr. 2007 Sep;86(3):s843-57. Review.

12.

Metabolic syndrome and the risk of prostate cancer in Finnish men: a population-based study.

Laukkanen JA, Laaksonen DE, Niskanen L, Pukkala E, Hakkarainen A, Salonen JT.

Cancer Epidemiol Biomarkers Prev. 2004 Oct;13(10):1646-50.

13.

Androgen-deprivation therapy and metabolic syndrome in men with prostate cancer.

Harrington JM, Schwenke DC, Epstein DR, Bailey DE Jr.

Oncol Nurs Forum. 2014 Jan 1;41(1):21-9. doi: 10.1188/14.ONF.21-29.

14.

[Metabolic syndrome and insulin resistance in patients with prostate cancer treated with androgen deprivation hormone].

Terrier JE, Mottet N.

Prog Urol. 2013 Feb;23(2):88-95. doi: 10.1016/j.purol.2012.09.008. Epub 2012 Oct 12. Review. French.

PMID:
23352300
15.

Adverse effects of androgen deprivation therapy in men with prostate cancer: a focus on metabolic and cardiovascular complications.

Collins L, Basaria S.

Asian J Androl. 2012 Mar;14(2):222-5. doi: 10.1038/aja.2011.109. Epub 2012 Feb 20. Review.

16.

Metabolic syndrome in prostate cancer: impact on risk and outcomes.

Karzai FH, Madan RA, Dahut WL.

Future Oncol. 2016 Aug;12(16):1947-55. doi: 10.2217/fon-2016-0061. Epub 2016 Apr 12. Review.

17.

Metabolic complications of androgen deprivation therapy for prostate cancer.

Saylor PJ, Smith MR.

J Urol. 2013 Jan;189(1 Suppl):S34-42; discussion S43-4. doi: 10.1016/j.juro.2012.11.017. Review.

PMID:
23234628
18.

Prostate cancer, androgen deprivation therapy, obesity, the metabolic syndrome, type 2 diabetes, and cardiovascular disease: a review.

Collier A, Ghosh S, McGlynn B, Hollins G.

Am J Clin Oncol. 2012 Oct;35(5):504-9. Review.

PMID:
21297430
19.

A prospective, randomized pilot study evaluating the effects of metformin and lifestyle intervention on patients with prostate cancer receiving androgen deprivation therapy.

Nobes JP, Langley SE, Klopper T, Russell-Jones D, Laing RW.

BJU Int. 2012 May;109(10):1495-502. doi: 10.1111/j.1464-410X.2011.10555.x. Epub 2011 Sep 20.

20.

The metabolic syndrome and its components in patients with prostate cancer on androgen deprivation therapy.

Morote J, Gómez-Caamaño A, Alvarez-Ossorio JL, Pesqueira D, Tabernero A, Gómez Veiga F, Lorente JA, Porras M, Lobato JJ, Ribal MJ, Planas J; ANAMET Investigators Group..

J Urol. 2015 Jun;193(6):1963-9. doi: 10.1016/j.juro.2014.12.086. Epub 2014 Dec 23.

PMID:
25541340

Supplemental Content

Support Center